AUS
NZ
UK
CA
USA
IND
Highlights
- Novartis announces $37B US manufacturing expansion
- 10 facilities planned, including six new plants
- Strategy aims to navigate US tariff uncertainty
Swiss pharmaceutical giant Novartis (SWX:NOVN) has unveiled plans for a significant expansion of its manufacturing footprint in the United States, committing US$23 billion (approximately A$37 billion) toward the construction and development of 10 facilities. This move comes in the wake of proposed tariff increases on pharmaceutical imports by the US government, signaling a strategic shift to localize production and mitigate potential supply chain disruptions.
Currently operating 33 manufacturing sites worldwide, Novartis intends to add six entirely new production plants over the next five years. While the company has not yet finalized the locations for four of the new sites, it confirmed that two will be built in Florida and Texas — states known for their strong pharmaceutical and biotech ecosystems.
This bold commitment follows closely behind a recent announcement by US President Donald Trump outlining plans for a major tariff on drug imports. The proposed policy has triggered uncertainty across the pharmaceutical industry, with companies now reassessing their global manufacturing strategies.
Despite the looming tariffs, Novartis leadership emphasized that the investment decision is rooted in a broader, long-term vision rather than a direct response to the proposed trade measures. In a recent interview, CEO Vas Narasimhan stated that while the tariffs could pose challenges, they are not the sole reason behind the investment.
"We believe we can manage the tariffs — though of course they will be very painful — so while that is a factor, it's not the driving factor," Narasimhan said.
Novartis appears to be aligning its production infrastructure with an evolving regulatory and commercial environment in the US. With increasing emphasis on domestic drug manufacturing and supply chain resilience, the company’s decision may also position it more competitively for future US government contracts and faster market access.
As the pharmaceutical industry faces increasing geopolitical and regulatory complexities, this large-scale US expansion positions Novartis to reinforce its commitment to American markets while staying agile in the face of global trade shifts.
The company’s move could also set a precedent for other multinational drugmakers to consider deeper local investments as a buffer against rising protectionist policies in key markets.
